Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Heparin Scare Sparks Global Look At Drug Imports

This article was originally published in PharmAsia News

Executive Summary

The recent alarm over tainted heparin produced in China has awakened nations around the world to a need for better protection against faulty imported drugs. Backed by congressional promises of more funds, the U.S. FDA plans to station inspectors in selected countries, including China, on a permanent basis instead of relying on inspections at the U.S. border. Regulators in China also have taken small steps to close loopholes in the local oversight system, but that means watching thousands of chemical companies selling pharmaceutical ingredients without a license. Chinese regulators face a daunting task since much of the basic work is done in unregulated family workshops. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068073

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel